不扭曲宫腔的子宫肌瘤与体外受精成功率:采用广泛匹配标准的观察性研究
这项回顾性匹配单中心队列研究分析了2011年1月1日至2015年5月1日接受体外受精/卵胞浆内单精子注射(IVF/ICSI)的不扭曲宫腔子宫肌瘤患者,按年龄、刺激方案、起始FSH剂量、移植胚胎数和移植日与无肌瘤对照匹配。结果显示肌瘤似乎负向影响临床妊娠(OR 0.62;95%CI 0.41-0.94)和活产率(OR 0.58;95%CI 0.48-0.78),在≥2个肌瘤和直径≥30 mm肌瘤中活产率影响显著。
要点
- 不扭曲宫腔的子宫肌瘤似乎负向影响首次IVF/ICSI周期的临床妊娠率(OR 0.62)和活产率(OR 0.58)。
- ≥2个肌瘤者活产率OR 0.47,肌瘤直径≥30 mm者活产率OR 0.41。
- 单个直径<30 mm肌瘤者妊娠结局无差异。
核心结论
- 不扭曲宫腔的子宫肌瘤似乎负向影响首次IVF/ICSI周期的临床妊娠率和活产率。
- 需要设计良好、把握度充分的随机对照试验来探讨药物或手术干预在肌壁间和浆膜下肌瘤患者接受生育治疗前的角色。
研究设计与样本
- 回顾性、匹配、单中心队列研究,地点为一家三级大学医院的IVF单元。
- 分析2011年1月1日至2015年5月1日所有接受IVF/ICSI周期的不扭曲宫腔子宫肌瘤女性。
- 每名患者按年龄(±6个月)、刺激方案(促性腺激素释放激素激动剂或拮抗剂)、起始卵泡刺激素(FSH)剂量、移植胚胎数(1或2个)、移植日(第3天或第5天)与两名无子宫肌瘤对照匹配。
主要发现
- 与匹配对照相比,不扭曲宫腔肌瘤患者首次IVF/ICSI周期的临床妊娠率OR 0.62(95%CI 0.41-0.94),活产率OR 0.58(95%CI 0.48-0.78)。
- ≥2个肌瘤者活产率OR 0.47(95%CI 0.26-0.83),肌瘤直径≥30 mm者活产率OR 0.41(95%CI 0.19-0.89)。
- 第5天移植者中肌瘤对活产率的负向影响仍存在(OR 0.58;95%CI 0.35-0.94)。
- 单个直径<30 mm肌瘤者妊娠结局无差异。
关键数值与推荐
- 临床妊娠OR 0.62(95%CI 0.41-0.94),活产OR 0.58(95%CI 0.48-0.78),对象为首次IVF/ICSI周期的不扭曲宫腔肌瘤患者与匹配对照比较。
- ≥2个肌瘤者活产OR 0.47(95%CI 0.26-0.83)。
- 肌瘤直径≥30 mm者活产OR 0.41(95%CI 0.19-0.89)。
- 第5天移植者活产OR 0.58(95%CI 0.35-0.94)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the impact of non-cavity-distorting fibroids on in vitro fertilisation (IVF) pregnancy outcomes. DESIGN: A retrospective, matched, single-centre, cohort study was performed. SETTING: The IVF unit of a tertiary, university hospital. POPULATION: We analysed all women with non-cavity-distorting uterine fibroids undergoing IVF/intracytoplasmic sperm injection (ICSI) cycles from 1 January 2011 to 1 May 2015. METHODS: Each woman was matched with two separate controls of the same age (±6 months), stimulation protocol (gonadotropin-releasing hormone agonist or antagonist), starting dose of follicle-stimulating hormone (FSH), number of embryos transferred (one or two), day of transfer (day 3 or day 5), and no uterine fibroids identified by transvaginal ultrasound. MAIN OUTCOME MEASURES: Clinical pregnancy and live birth rates. RESULTS: Our study demonstrates that the presence of non-cavity-distorting fibroids appears to negatively affect clinical pregnancy (odds ratio, OR 0.62; 95% confidence interval, 95% CI 0.41-0.94) and live birth rates (OR 0.58; 95% CI 0.48-0.78) in patients undergoing their first IVF/ICSI cycle, when matched with controls of the same age, starting dose of FSH, stimulation protocol, number of embryos, and day of embryo transfer. The deleterious effect of fibroids on live birth rates was significant in women with two or more fibroids (OR 0.47; 95% CI 0.26-0.83) and in women with fibroids of ≥30 mm in diameter (OR 0.41; 95% CI 0.19-0.89). The negative impact of non-cavity-distorting fibroids was also present in women with an embryo transfer on day 5 (OR 0.58; 95% CI 0.35-0.94). Conversely, in women with single fibroids of <30 mm in diameter, no difference in pregnancy outcomes was identified. CONCLUSIONS: A well-designed, adequately powered, randomised controlled trial is required to address the role of medical or surgical interventions in patients with intramural and subserosal fibroids before undergoing fertility treatment. TWEETABLE ABSTRACT: Non-cavity-distorting fibroids negatively affect pregnancy rates after IVF.
引用
- Christopoulos G, Vlismas A, Salim R, et al. Fibroids that do not distort the uterine cavity and IVF success rates: an observational study using extensive matching criteria. BJOG. 2016. PMID: 27921379. doi:10.1111/1471-0528.14362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。